MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
AIkido Pharma Cash and Cash Equivalents 2011-2026 | AIKI
Annual Cash and Cash Equivalents AIkido Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 M | 4.08 M | 2.83 M | 33.2 M | 65.6 M | 2.72 M | 91 K | 17 K | 197 K | 134 K | 142 K | 805 K | 3.12 M | 4.5 M | 4.91 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.6 M | 17 K | 10.4 M |
Quarterly Cash and Cash Equivalents AIkido Pharma
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.37 M | 4.08 M | 3.4 M | 5.8 M | 1.96 M | 2.83 M | 4.39 M | 3.6 M | 9.53 M | 33.2 M | 34.5 M | 38.8 M | 49.7 M | 65.6 M | 5.95 M | 7.72 M | 7.98 M | 2.72 M | 2.72 M | 2.72 M | 2.72 M | 91 K | 91 K | 91 K | 91 K | 17 K | 17 K | 17 K | 22 K | 197 K | 197 K | 197 K | 197 K | 134 K | 134 K | 134 K | 134 K | 142 K | 142 K | 142 K | 142 K | 805 K | 805 K | 805 K | 805 K | 3.12 M | 3.12 M | 3.12 M | 3.12 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.91 M | 4.91 M | 4.91 M | 4.91 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.6 M | 17 K | 6.16 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Cerus Corporation
CERS
|
20 M | $ 2.68 | -1.65 % | $ 511 M |  USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 96.56 | -2.81 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
Edesa Biotech
EDSA
|
1 M | $ 15.71 | -2.48 % | $ 50.2 M | USA |
 |
Evogene Ltd.
EVGN
|
13 M | $ 0.78 | 4.15 % | $ 27.9 M |  Israel |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
6.95 M | - | - | $ 2.46 M | Israel |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Genmab A/S
GMAB
|
3.55 B | - | - | $ 16.9 B |  Danmark |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
753 M | - | - | $ 1.87 B | USA |
 |
ImmuCell Corporation
ICCC
|
3.81 M | $ 8.78 | 0.71 % | $ 79.2 M | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
Innoviva
INVA
|
551 M | $ 22.78 | -0.91 % | $ 1.54 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | - | - | $ 235 M | France |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.3 | 0.5 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
968 K | $ 2.83 | -13.08 % | $ 6.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | - | - | $ 109 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
229 M | $ 26.7 | 0.15 % | $ 1.44 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | - | - | $ 5.75 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
25.4 M | - | -9.21 % | $ 2.55 M | USA |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.24 | -0.62 % | $ 260 M | Israel |
 |
Eloxx Pharmaceuticals
ELOX
|
19.2 M | - | -5.68 % | $ 8.28 M | USA |